Title:Gut Microbiota as an Emerging Therapeutic Avenue for the Treatment of Nonalcoholic Fatty Liver Disease
Volume: 27
Issue: 46
Author(s): Tanya Ralli*, Yub Raj Neupane, Zoya Saifi and Kanchan Kohli*
Affiliation:
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062,India
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062,India
Keywords:
NAFLD, gut liver axis, microbiota, microbiome, dysbiosis, Bifidobacterium, Faecalibacterium.
Abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the leading causes of death related to liver diseases
worldwide. Despite this, there is no specific treatment approved for the disease till now, which could be
due to the poor understanding of the pathophysiology of this disease. In the past few decades, several scientists
have speculated the root cause of NAFLD to be dysbalance in the gut microbiome resulting in a susceptibility
to the inflammatory cascade in the liver. Herein, we hypothesize to fabricate a novel formulation containing prebiotic
with probiotics which thereby would help in maintaining the gut homeostasis, and be used for the treatment
of NAFLD. The proposed novel formulation would contain a Bifidobacterium sp. with Faecalibacterium
prausnitzii in the presence of a dietary fibre having hepatoprotective activity. These two strains of probiotics
would help in increasing the concentration of butyrate in the gut which in turn would inhibit intestinal inflammation
and maintain gut integrity. The dietary fibre would serve a dual mechanism; firstly, it would act as a prebiotic
helping in the proliferation of administered probiotics, and secondly, it would protect the liver via its own
hepatoprotective action. This combinatorial approach would pave a new therapeutic avenue for the treatment of
NAFLD.
